DOI: http://dx.doi.org/10.18203/2349-3933.ijam20210606

The treatments of COVID-19 patient with diabetes mellitus: a case report

I. Gede Sadu Pratamawerdi, Jason Raymond Hotama, I. Made Suma Wirawan

Abstract


Diabetes mellitus or uncontrolled blood sugar is one of the factors causing the severity risk of COVID-19 infection. The researchers from China and Italy also find a profound connection of the old age patients who have chronic illness comorbid are tend to have a higher risk of enduring serve COVID-19, and have a higher number of deaths. Until this report is written, there are no medicines nor vaccines to treat COVID-19 completely. This article reports KTK, a 57 years old woman, Balinese, was diagnosed with COVID-19 and was treated because of the loss of consciousness. Patient had already done the op debridement amputation for left foot digit II-V and the wound of the patient got worsen. Patient also had blood sugar variability which complicated the insulin therapy and inhibits the patient’s recovery. On her way, the patient’s respiratory system got worsen. Diabetes is strongly connected with a higher risk of severe COVID-19 and has a higher death rate compared to controlled blood sugar. The purpose of the guidance for COVID-19 patients with Diabetes is to prove that comprehensive glycemic control and blood glucose monitoring have a good result of the treatments for COVID-19 patients with Diabetes, also reduce the complication from the comorbid of chronic illness (diabetes), and avoiding the undesirable possibilities about the treatments.


Keywords


COVID-19, Diabetes mellitus, Treatment

Full Text:

PDF

References


Williams R, Karuranga S, Malanda B, Saeedi P, Basit A, Besançon S. Global and regional estimates and projections of diabetes-related health expenditure: results from the International Diabetes Federation Diabetes Atlas. Diabetes Res Clin Pract. 2020;162.

Sen L, Jiaxin W, Biao Z, Xinyi L, Yuan L. Diabetes mellitus and cause-specific mortality: a population-based study. Diabetes Metab J. 2019;43(3):319.

Yang JK, Feng Y, Yuan MY, Yuan SY, Fu HJ, Wu BY Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS. Diabet Med. 2006;23(6):623-28.

Rani BG, Salem AA, Robert B, Harunor R. Risk factors for severity and mortality in patients with MERS-CoV: analysis of publicly available data from Saudi Arabia. Virol Sin. 2016;31(1):81-84.

Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;1-13.

Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA. 2020.

Aihong W, Weibo Z, Zhangrong X, Jianwen G. Timely blood glucose management for the outbreak of 2019 novel coronavirus disease (COVID-19) is urgently needed. Diabetes Res Clin Pract. 2020;162:108-118.

Sylvia K. Diabetes and infection: is there a link? - A mini-review. Gerontology. 2013;59(2):99-104.

Iqbal A, Prince LR, Novodvorsky P, Bernjak A, Thomas MR, Birch L. Effect of hypoglycemia on inflammatory responses and the response to low-dose endotoxemia in humans. J Clin Endocrinol Metab. 2019;104(4):1187-199.

Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269-71.

Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020;14(1):72-3.

Rekedal LR, Massarotti E, Garg R, Bhatia R, Gleeson T, Lu B. Changes in glycosylated hemoglobin after initiation of hydroxychloroquine or methotrexate treatment in diabetes patients with rheumatic diseases. Arthritis Rheum. 2010;62(12):3569-573.

Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020;395(10223):473-75.

World Health Organization. Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected. Interim guidance, 13 March 2020 Geneva2020. https://www.thelancet.com/action/showPdf?pii=S0140-6736%2820%2930317-2. Last accessed on 2nd November, 2020.